logo
Water on Mars? Mysterious Dark Streaks Aren't What Scientists Thought

Water on Mars? Mysterious Dark Streaks Aren't What Scientists Thought

Gizmodo25-05-2025

Scientists have been arguing about the origin of strange streaks on Mars since the earliest missions to the Red Planet.
In 1976, NASA's Viking mission successfully landed the first spacecraft on Mars. When the mission began sending images from Mars' surface back to Earth, scientists noted long, dark streaks on crater walls and cliff sides. To this day, some researchers suggest that the strange geographical features are the result of water flow—but a recent study says otherwise.
Planetary scientists from Brown University and the University of Bern have used artificial intelligence to reveal that the enigmatic Martian streaks likely result from wind and dust, not water flow. Their results have important implications for future Mars exploration, as well as humanity's continuous search for habitable environments and life beyond Earth.
Some slope streaks are long-lasting, while others—called recurring slope lineae (RSL)—are more ephemeral, continuously appearing in the same places during Mars' hottest times of the year. Although Mars is generally dry and cold (with temperatures as low as -225 degrees Fahrenheit, or -153 degrees Celsius) small amounts of water from potential ice, underground sources, or humidity could conceivably mix with enough salt to become liquid and flow down a slope. Because water is a key ingredient for life on Earth, such formations might represent habitable regions on the Red Planet, too. But some researchers aren't convinced, arguing that dry processes could have created those features instead.
To settle the matter, the researchers trained an algorithm on a dataset of confirmed slope streak sightings, as detailed in a study published Monday in the journal Nature Communications. They then used the algorithm to scan over 86,000 high-resolution satellite images and compose a map of Martian slope streaks.
'Once we had this global map, we could compare it to databases and catalogs of other things like temperature, wind speed, hydration, rock slide activity and other factors,' Valentin Bickel, co-author of the study and a University of Bern Center for Space and Habitability fellow, said in a Brown University statement. 'Then we could look for correlations over hundreds of thousands of cases to better understand the conditions under which these features form.'
Simply put, their results do not link slope streaks and RSLs with features indicating the presence of liquid or even frost. Instead, the researchers discovered that both slope streaks and RSLs tend to develop in areas with high wind speed and dust deposition. In other words, they are likely caused by a dry process in which dust layers abruptly slide down a slope, triggered by external forces.
Rather than seeing these results as yet another failure in our search for extraterrestrial life, the planetary scientists explain that the study still carries weight for future Mars explorations. If their research had confirmed the theory that slope streaks were caused by water, and that as a result the region might host some form of life, NASA would have actually avoided the area for the time being. That's because scientists fear that spacecraft and rovers might still harbor terrestrial life, such as microbes, which could contaminate Martian habitats and interfere with our search for Martian life.
'That's the advantage of this big data approach,' explained Adomas Valantinas, the other co-author of the study and a planetary scientist at Brown University who specializes in Martian geology. 'It helps us to rule out some hypotheses from orbit before we send spacecraft to explore.'
In an industry that seems obsessed with finding water on Mars, the study stands as a reminder that not every scientific breakthrough needs to be about extraterrestrial life.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

With 'Atmosphere,' Taylor Jenkins Reid leaves the Evelyn Hugo-verse behind and travels to space
With 'Atmosphere,' Taylor Jenkins Reid leaves the Evelyn Hugo-verse behind and travels to space

Washington Post

timean hour ago

  • Washington Post

With 'Atmosphere,' Taylor Jenkins Reid leaves the Evelyn Hugo-verse behind and travels to space

Taylor Jenkins Reid recalls a moment writing her new novel, 'Atmosphere: A Love Story,' set against NASA's robust 1980s shuttle program, where she felt stuck. She went, where she often goes, to her husband to talk it through. 'I said, 'I can't write this book. I don't know enough about the space shuttle. I don't know what happens when the payload bay doors won't shut and you have to get back within a certain amount of revs, but they can't land at White Sands. They have to land at Cape Kennedy.' And he's like, 'Just listen to yourself. You know so much more than you knew a couple months ago. Keep doing what you're doing.''

Same-Day Discharge Criteria Outlined for AF Ablation
Same-Day Discharge Criteria Outlined for AF Ablation

Medscape

timean hour ago

  • Medscape

Same-Day Discharge Criteria Outlined for AF Ablation

SAN DIEGO — Same-day discharge after ablation of atrial fibrillation (AF) is an appropriate strategy for saving costs if performed with strict selection criteria and protocols, according to a recently issued joint statement from the American College of Cardiology and the Heart Rhythm Society. Same-day discharge has long been indicated for catheter ablations to abort routine atrial flutter, atrioventricular nodal reentrant tachycardia, and focal atrial tachycardias, according to the authors of the new joint statement. Although they maintained patients selected for elective catheter ablation of AF require heightened scrutiny, they endorsed same-day AF ablation when used selectively. The statement evaluates 'evidence supporting shorter hospitalization stay with same-day discharge for intracardiac ablations agonistic to site of care,' reported Amit J. Shankar, MD , an electrophysiologist with Canton-Potsdam Hospital in Potsdam, New York, who served as a representative for the Heart Rhythm Society in developing the statement. Whether in a hospital setting or an outpatient facility, the statement describes same-day discharge ablation as an opportunity to improve patient access, improve efficiency, and reduce healthcare costs. The adoption of same-day discharge after AF ablation was accelerated during the COVID-19 pandemic, said Samuel O. Jones, MD, a cardiologist affiliated with The Chattanooga Heart Institute in Chattanooga, Tennessee, and a fellow of the American College of Cardiology. 'Improved workflows, technological innovations, and procedure advancements have also contributed to the high rates at which these are performed,' added Jones, who helped write the statement. The statement was released on April 24 to coincide with the first day of the Heart Rhythm Society (HRS) 2025 annual scientific meeting. It was simultaneously published in Heart Rhythm and the Journal of the American College of Cardiology . The scientific statement's recommendation is intended for elective rather than urgent or emergency ablations. Support for the statement was drawn from multiple case-controlled studies, meta-analyses, and outcome databases. In one example, a 12-study meta-analysis with data from more than 18,000 elective ablations showed no significant differences in major complications from the procedure among the 40.5% of patients discharged the same day relative to those who were discharged after at least one night in the hospital. In another study, drawn from a real-world prospective registry, outcomes were compared for potential candidates for same-day ablation on the basis of prespecified criteria and those who were not eligible for the procedure. These criteria included no bleeding history, a left ventricular ejection fraction greater than 40%, no pulmonary disease, and no surgical procedures within the previous 60 days. Of the 2332 patients included in the analysis, 1982 (85%) were deemed candidates for same-day ablation. Although freedom for atrial arrhythmias was comparable ( P = .0212) for the two groups, patients discharged the same day had a lower rate of complications (0.8% vs 2.9%; P < .001). The rate of readmission was similar (0.8% vs 09%; P = .924), according to the researchers. Contraindications for Same-Day Ablation In the document, relative contraindications for same-day ablation include decompensated heart failure, significant pulmonary disease, significant risk of bleeding, and any major unstable comorbidities such as diabetes, hypertension, or renal disease. The document recommends limiting same-day procedures to patients who can have readily available social support and can return to a hospital quickly in the event of a post-procedural complication. Acknowledging that most large hospitals offering ablation for AF already have formal selection criteria and protocols in place for same-day discharge, the authors called for free-standing sites to establish their own if they have not done so. In these settings, the authors emphasized the need to rigorously follow prespecified and 'ironclad' selection criteria and protocols. From this standpoint, Shankar said same-day procedures should always be performed on the basis of shared decision-making with the patient. While the economic benefits of same-day procedures might be shared by the facility and the patient, the latter should understand the inherent differences in the settings and participate actively in any decision of where the ablation is performed. Jones said while a substantial body of evidence supports same-day AF ablation as a safe and effective procedure that can free up necessary resources in the healthcare facility, the potential advantages are relevant only to appropriately selected patients. The new statement also suggests transfer agreements with inpatient facilities should be arranged in advance and that patients should be informed such a transfer is a possibility outside of a hospital setting. However, the document makes clear same-day ablations in alternative sites of care are reasonable when the precautions are observed. In any setting that AF ablation is performed, the writing committee encouraged tracking outcomes to ensure that high-quality care is achieved and sustained. Shankar and Jones reported no potential conflicts of interest.

Umbrella Labs Expands Research Portfolio with Availability of Retatrutide (LY3437943), a Next-Generation Triple Agonist Peptide
Umbrella Labs Expands Research Portfolio with Availability of Retatrutide (LY3437943), a Next-Generation Triple Agonist Peptide

Yahoo

timean hour ago

  • Yahoo

Umbrella Labs Expands Research Portfolio with Availability of Retatrutide (LY3437943), a Next-Generation Triple Agonist Peptide

TUCSON, AZ / / June 2, 2025 / Umbrella Labs, a leading supplier of advanced research chemicals, announced the expansion of its peptide catalog to include Retatrutide (LY3437943), an investigational triple agonist peptide developed for use in scientific and academic research. This addition marks a significant milestone in the company's commitment to supporting cutting-edge research in metabolic disease, obesity, and type 2 diabetes mellitus (T2DM). Retatrutide has gained attention within the scientific community due to its unique ability to activate three key receptors involved in metabolic regulation: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This multi-receptor mechanism offers a promising new direction for researchers investigating novel treatments for obesity-related diseases. "We are proud to offer Retatrutide as part of our mission to provide academic and institutional researchers with the most innovative compounds available," said Samuel Yanner, Director of Scientific Operations at Umbrella Labs. "The peptide's clinical and preclinical data demonstrate its potential as a transformative research molecule." Scientific Highlights: Preclinical and Clinical Validation In comparative rodent studies, Retatrutide outperformed GLP-1 monotherapy and the dual agonist Tirzepatide, producing over 30% weight reduction while improving liver lipid profiles, insulin sensitivity, and inflammatory markers (Ma et al., 2025). A Phase 2 human trial led by Jastreboff et al. (2023) demonstrated up to 24.2% weight loss in non-diabetic obese participants, along with significant improvements in blood pressure, fasting glucose, LDL cholesterol, and HbA1c. These outcomes exceed the performance benchmarks of currently approved GLP-1-based therapeutics, including semaglutide. Expanding Research Horizons: Metabolic, Hepatic, and Cardiovascular Implications Retatrutide's diverse effects have fueled interest in multiple areas of academic investigation: Obesity and Weight Management: The triple receptor action mimics metabolic responses seen in bariatric surgery, with non-invasive delivery. T2DM Research: Demonstrated reductions in HbA1c (up to 2.2%) and possible β-cell preservation. NAFLD/NASH Models: Reduction in hepatic fat, ALT/AST normalization, and improved lipid oxidation suggest promising utility. Cardiovascular Metrics: Lower CRP and triglycerides, with HDL elevation, signal potential long-term cardiac benefit. Emerging exploratory areas include microdosing studies in appetite regulation, mitochondrial function, and speculative neuroendocrine roles due to GLP-1 expression in the central nervous system. Commitment to Quality: Umbrella Labs as a Trusted Supplier Retatrutide remains an investigational compound not approved for human use and is offered strictly for in vitro and animal-based research by qualified institutions. Umbrella Labs ensures cGMP-compliant manufacturing, third-party analytical testing, and reliable batch documentation for all peptides. Researchers interested in sourcing Retatrutide can find the compound listed at:Buy Retatrutide (LY3437943) - Umbrella Labs For additional research peptides and SARMs, visit the Umbrella Labs homepage. About Umbrella Labs Umbrella Labs is a premier supplier of research-grade peptides, SARMs, and other investigational compounds used by universities, pharmaceutical developers, and independent research teams. With a focus on purity, testing transparency, and customer support, Umbrella Labs continues to lead the field in supplying next-generation biochemicals for science-driven innovation. Media Contact Samuel YannerDirector of Scientific OperationsUmbrella Labs1-866-289-7276support@ E Hemisphere Loop, Tucson, AZ 85706 References Coskun T, Sloop KW, Loghin C, et al. LY3437943, a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Improves Metabolic Parameters in Preclinical Models of Obesity. Cell Metab. 2018;28(5):710-722.e10. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Triple-hormone-receptor agonist Retatrutide in adults with obesity: a randomized, double-blind, phase 2 trial. N Engl J Med. 2023;389(13):1134-1145. Ma X, Zhang L, Su Y, et al. Comparative efficacy of GLP-1/GIP/glucagon receptor agonism in diabetic mice: insights into Retatrutide's hepatometabolic benefits. J Endocrinol Invest. 2025;48(1):55-66. Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19(4):277-289. Killion EA, Wang J, Yie J, et al. Glucagon receptor activation increases energy expenditure and modulates lipoprotein metabolism in mice. Proc Natl Acad Sci USA. 2018;115(5):E1051-E1060. SOURCE: Umbrella Labs View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store